Hormonal
Excessive dietary fructose consumption (particularly from sugar-sweetened beverages) drives the development of Non-Alcoholic Fatty Liver Disease (NAFLD) and metabolic syndrome by stimulating hepatic de novo lipogenesis (DNL) and increasing VLDL secretion.
Limit intake of added sugars, specifically fructose and high-fructose corn syrup, found in sugar-sweetened beverages and processed foods. This is particularly critical if you have abdominal obesity or metabolic risk factors, as fructose uniquely drives liver fat accumulation and triglyceride production independent of total weight gain.
Accumulating evidence supports the fact that fructose is an important mediator for the development of NAFLD and a main driver for DNL [64].
Why this rating
The paper cites multiple human intervention studies (MRI quantification, stable isotopes) and large cohort studies, though it acknowledges some conflicting data on isocaloric intake.
Source
Dietary Fructose and the Metabolic Syndrome
Marja‐Riitta Taskinen et al. · Nutrients · 2019
DOI 10.3390/nu11091987
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →